TABLE 1.
Characteristics of patients who received ICI treatment (n = 148)
| n |
Oligo n ＝ 38 |
Non‐oligo n ＝ 110 | P‐value | |
|---|---|---|---|---|
| Age, median (range) | 65 (37‐87) | 68 (48‐87) | 64 (37‐82) | |
| Sex, female/male | 41/107 | 5/33 | 36/74 | .021 |
| ECOG performance status, 0/1/2 | 52/91/5 | 17/20/1 | 35/71/4 | .35 |
| Driver mutation | ||||
| Positive (%) | 43 a (29%) | 8(21%) | 35 (32%) | .300 |
| Histology | ||||
| Ad/Sq/other | 87/41/20 | 15/15/8 | 72/26/12 | .019 |
| Smoking history | ||||
| Yes/No | 118/30 | 35/3 | 83/27 | .034 |
| Stage | ||||
| Postoperative recurrence/III/IV | 16/29/103 | 6/6/26 | 10/23/77 | .458 |
| ICI treatment | ||||
| Nivolumab/Pembrolizumab | 106/42 | 25/13 | 81/29 | .406 |
| ICI line | ||||
| 1/2/3 or later | 20/76/52 | 9/20/9 | 11/56/43 | .054 |
| Response to PD‐1 blockade | ||||
| PR | 33 | 20 | 13 | |
| SD | 20 | 7 | 13 | |
| PD | 95 | 11 | 84 | |
| ORR | 22.3% | 52.6% | 11.8% | <.0001 |
| PFS | ||||
| Within 6 mo/over 6 mo | 104/44 | 14/24 | 90/20 | <.0001 |
Abbreviations: Ad, adenocarcinoma; ECOG, Eastern Cooperative Group; ICI, immune checkpoint inhibitor; Non‐oligo, non‐oligoprogression; Oligo, oligoprogression; ORR, objective response rate; PD, progressive disease; PFS, progression‐free survival; PR, partial response; SD, stable disease; Sq, squamous cell carcinoma.
a
Major driver gene alterations were not evaluated in 4 patients because of the presence of pure squamous cell carcinoma histology.